Benefits of Neoadjuvant Chemotherapy for Luminal Breast Cancer with Respect to Tumor Response
Received Date : 01 May 2020
Accepted Date : 17 Sep 2020
Available Online : 03 Feb 2021
Doi: 10.37047/jos.2020-75852 - Article's Language: EN
J Oncol Sci. 2021;7(1):7-14
This is an open access article under the CC BY-NC-ND license
Objective: The pathological complete response (PCR) rate following neoadjuvant chemotherapy (NAC) is prognostic for overall survival (OS). We evaluated the pathological responses to NAC and related factors in luminal type HER2-positive breast cancer. Materials and Methods: Hormone receptor (H), HER2/neu status, and Ki67 index were evaluated on 258 core biopsies of breast cancer before NAC. In total, 194 cancer core biopsies were found to be luminal A or B. A Ki67 index of above 20% together with hormone receptor positivity and HER2 negativity further confirmed the breast cancer type as luminal B. The relation between pathological responses and the data obtained were evaluated using the Chi-square test. The OS and disease-free survival (DFS) and related factors were analyzed with univariate analysis. Results: PCR was achieved in 47 (18.2%) patients, and the objective response was 70.2% after NAC. The 5-year DFS rate was 59.2% that related to surgery type; T, N, and postoperative stages; lymphovascular invasion (LVI); perineural invasion (PNI); and pathological response to NAC (p < 0.001). The median OS could not be reached, and the 5-year OS rate was 88.5%. Furthermore, the N and postoperative stages, recurrence, and pathological response to NAC were related to OS. The hormone receptor positivity was related to pathological response (p = 0.03). Although partial and complete responses were high among hormone receptor-negative tumors, the stable response was more common among hormone receptor-positive ones. Conclusions: It should be better to recommend NAC to hormone receptor-negative or HER2-positive tumors unless surgery could not be performed because of the locally advanced tumor due to lower rate of PCR or partial response with NAC in hormone receptor-positive tumors.
  1. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342-3354. [Crossref]  [PubMed] 
  2. Beasley GM, Olson JA Jr. What's new in neoadjuvant therapy for breast cancer? Adv Surg. 2010;44:199-228. [Crossref]  [PubMed] 
  3. De La Cruz LM, Harhay MO, Zhang P, Ugras S.Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy. Ann Surg Oncol. 2018 ;25:3535-3540. [Crossref]  [PubMed] 
  4. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009;101:1529-1536. [Crossref]  [PubMed]  [PMC] 
  5. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-172. [Crossref] 
  6. Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, et al. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol. 2009 ;35:113-122. [Crossref]  [PubMed] 
  7. Von Minckwitz G, Blohmer J, Vogel P, Hanusch C, Eidtmann H, et al. Comparison of neoadjuvant 6 vs 8 cycles of dosetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study. J Clin Oncol. 2006;24:576 (abstract). [Crossref] 
  8. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 ;30:1796-1804. [Crossref]  [PubMed] 
  9. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006;56:37-47. [Crossref]  [PubMed] 
  10. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
  11. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084-2090. [Crossref]  [PubMed] 
  12. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785. [Crossref]  [PubMed] 
  13. Gentile LF, Plitas G, Zabor EC, Stempel M, Morrow M, et al. Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. Ann Surg Oncol. 2017;24:3896-3902. [Crossref]  [PubMed]  [PMC] 
  14. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 ;24:1037-1044. [Crossref]  [PubMed] 
  15. Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol. 2012;23 Suppl 10:x243-248. [Crossref]  [PubMed] 
  16. Babyshkina N, Malinovskaya E, Patalyak S, Bragina O, Tarabanovskaya N, et al. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Med Oncol. 2014 ;31:165. [Crossref]  [PubMed] 
  17. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009 ;116:359-369 [Crossref]  [PubMed] 
  18. Petit T, Wilt M, Velten M, Millon R, Rodier JF, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205-211. [Crossref] 
  19. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011;9:48-57. [Crossref]  [PubMed]  [PMC] 
  20. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. [Crossref]  [PubMed]  [PMC] 
  21. Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015;13:303. [Crossref]  [PubMed]  [PMC] 
  22. Whitworth P, Beitsch P, Mislowsky A, Pellicane JV, Nash C, et al. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. Ann Surg Oncol. 2017;24:669-675. [Crossref]  [PubMed]  [PMC]